PlateletBio Completes $75.5M Series B Financing

PlateletBio Completes $75.5M Series B Financing

PlateletBio, a preclinical-stage biotechnology company pioneering an entirely new platform of allogeneic cell therapies based on platelet biology, today announced that it has raised $75.5 million in Series B financing. The round includes new investors SymBiosis, K2 HealthVentures and Oxford Finance as well as participation from existing investors Ziff Capital Partners and Qiming Venture Partners. Read more >>

Share this post